Cancer, inflammation, and therapy: Effects on cytochrome P450-mediated drug metabolism and implications for novel immunotherapeutic agents

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 4, 2014, Pages 449-457

  Donald Harvey, R ^a   Morgan, E T ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450; CYTOKINE; IMMUNOLOGIC FACTOR;

ADAPTIVE IMMUNITY; ANIMAL; DRUG INTERACTION; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; INNATE IMMUNITY; METABOLISM; NEOPLASMS;

ADAPTIVE IMMUNITY; ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOKINES; DRUG INTERACTIONS; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INFLAMMATION; NEOPLASMS;

EID: 84921681871     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.143     Document Type: Article

References (75)

1. Parihar, A., Eubank, T.D. & Dosef, A.I. Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death. J. Innate Immun. 2, 204-215 (2010).
2. Medzhitov, R. & Janeway, C.A. Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91, 295-298 (1997).
3. Blasius, A.L. & Beutler, B. Intracellular toll-like receptors. Immunity 32, 305-315 (2010).
4. Kumagai, Y. & Akira, S. Identifcation and functions of pattern-recognition receptors. J. Allergy Clin. Immunol. 125, 985-992 (2010).
5. Takeuchi, O. & Akira, S. Pattern recognition receptors and infammation. Cell 140, 805-820 (2010).
6. Paul, W.E. & Zhu, J. How are T(H)2-type immune responses initiated and amplifed? Nat. Rev. Immunol. 10, 225-235 (2010).
7. Wahl, S.M., Allen, J.B., Wong, H.L., Dougherty, S.F. & Ellingsworth, L.R. Antagonistic and agonistic efects of transforming growth factor-beta and IL-1 in rheumatoid synovium. J. Immunol. 145, 2514-2519 (1990).
8. Moore, K.W., O'Garra, A., de Waal Malefyt, R., Vieira, P. & Mosmann, T.R. Interleukin-10. Annu. Rev. Immunol. 11, 165-190 (1993).
9. Grivennikov, S.I., Greten, F.R. & Karin, M. Immunity, infammation, and cancer. Cell 140, 883-899 (2010).
10. Kimball, A.B., Schenfeld, J., Accortt, N.A., Anthony, M.S., Rothman, K.J. & Pariser, D. Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. Br. J. Dermatol. 170, 366-373 (2014).
11. Harvey, A.E., Lashinger, L.M. & Hursting, S.D. The growing challenge of obesity and cancer: an infammatory issue. Ann. NY Acad. Sci. 1229, 45-52 (2011).
12. Park, E.J. et al. Dietary and genetic obesity promote liver infammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197-208 (2010).
13. Balkwill, F. & Mantovani, A. Infammation and cancer: back to Virchow? Lancet 357, 539-545 (2001).
14. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
15. Swann, J.B. & Smyth, M.J. Immune surveillance of tumors. J. Clin. Invest. 117, 1137-1146 (2007).
16. Blumentals, W.A., Foulis, P.R., Schwartz, S.W. & Mason, T.J. Analgesic therapy and the prevention of bladder cancer. Urol. Oncol. 22, 11-15 (2004).
17. Fortuny, J. et al. Analgesic and anti-infammatory drug use and risk of bladder cancer: a population based case control study. BMC Urol. 7, 13 (2007).
18. Cook, N.R. et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294, 47-55 (2005).
19. Limburg, P.J. et al.; Cancer Prevention Network. Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fber for colorectal cancer chemoprevention. Cancer Prev. Res. (Phila). 4, 259-269 (2011).
20. Il'yasova, D. et al. Circulating levels of infammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol. Biomarkers Prev. 14, 2413-2418 (2005).
21. Morgan, E.T. Impact of infectious and infammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin. Pharmacol. Ther. 85, 434-438 (2009).
22. Morgan, E.T. Regulation of cytochrome p450 by infammatory mediators: why and how? Drug Metab. Dispos. 29, 207-212 (2001).
23. Morgan, E.T. et al. Regulation of drug-metabolizing enzymes and transporters in infection, infammation, and cancer. Drug Metab. Dispos. 36, 205-216 (2008).
24. Theken, K.N., Deng, Y., Kannon, M.A., Miller, T.M., Poloyac, S.M. & Lee, C.R. Activation of the acute infammatory response alters cytochrome P450 expression and eicosanoid metabolism. Drug Metab. Dispos. 39, 22-29 (2011).
25. Panigrahy, D., Kaipainen, A., Greene, E.R. & Huang, S. Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev. 29, 723-735 (2010).
26. Evers, R. et al. Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper. Drug Metab. Dispos. 41, 1598-1609 (2013).
27. Aitken, A.E., Richardson, T.A. & Morgan, E.T. Regulation of drug-metabolizing enzymes and transporters in infammation. Annu. Rev. Pharmacol. Toxicol. 46, 123-149 (2006).
28. Abdel-Razzak, Z. et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol. Pharmacol. 44, 707-715 (1993).
29. Muntané-Relat, J., Ourlin, J.C., Domergue, J. & Maurel, P. Diferential efects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 22, 1143-1153 (1995).
30. Aitken, A.E. & Morgan, E.T. Gene-specifc efects of infammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab. Dispos. 35, 1687-1693 (2007).
31. Siewert, E., Bort, R., Kluge, R., Heinrich, P.C., Castell, J. & Jover, R. Hepatic cytochrome P450 down-regulation during aseptic infammation in the mouse is interleukin 6 dependent. Hepatology 32, 49-55 (2000).
32. Kacevska, M., Robertson, G.R., Clarke, S.J. & Liddle, C. Infammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin. Drug Metab. Toxicol. 4, 137-149 (2008).
33. Kacevska, M., Mahns, A., Sharma, R., Clarke, S.J., Robertson, G.R. & Liddle, C. Extra-hepatic cancer represses hepatic drug metabolism via interleukin (IL)-6 signalling. Pharm. Res. 30, 2270-2278 (2013).
34. Nyagode, B.A., Lee, C.M. & Morgan, E.T. Modulation of hepatic cytochrome P450s by Citrobacter rodentium infection in interleukin-6-and interferon-{gamma}-null mice. J. Pharmacol. Exp. Ther. 335, 480-488 (2010).
35. Schmitt, C., Kuhn, B., Zhang, X., Kivitz, A.J. & Grange, S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin. Pharmacol. Ther. 89, 735-740 (2011).
36. Islam, M. et al. Diferential efect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin. Cancer Res. 8, 2480-2487 (2002).
37. Wu, J.J. & Fleming, K.F. Interaction between adalimumab with concurrent pregabalin and duloxetine administration in a psoriasis patient with diabetic peripheral neuropathy. Cutis 87, 249-250 (2011).
38. Ling, S. & Jamali, F. The efect of infiximab on hepatic cytochrome P450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: a drug-disease and drug-drug interaction. Basic Clin. Pharmacol. Toxicol. 105, 24-29 (2009).
39. Gupta, R., Levin, E., Wu, J.J., Koo, J. & Liao, W. An update on drug-drug interactions with biologics for the treatment of moderate-to-severe psoriasis. J. Dermatolog. Treat. 25, 87-89 (2014).
40. Dallas, S., Chattopadhyay, S., Sensenhauser, C., Batheja, A., Singer, M. & Silva, J. Interleukins-12 and-23 do not alter expression or activity of multiple cytochrome P450 enzymes in cryopreserved human hepatocytes. Drug Metab. Dispos. 41, 689-693 (2013).
41. Vogelzang, N.J., Priest, E.R. & Borden, L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J. Urol. 148, 1247-1248 (1992).
42. Printz, C. Spontaneous regression of melanoma may ofer insight into cancer immunology. J. Natl. Cancer Inst. 93, 1047-1048 (2001).
43. Shord, S.S. et al. Cytochrome P450 2C9 mediated metabolism in people with and without cancer. Int. J. Clin. Pharmacol. Ther. 46, 365-374 (2008).
44. Charles, K.A., Rivory, L.P., Brown, S.L., Liddle, C., Clarke, S.J. & Robertson, G.R. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin. Cancer Res. 12, 7492-7497 (2006).
45. Baker, S.D. et al. Factors afecting cytochrome P-450 3A activity in cancer patients. Clin. Cancer Res. 10, 8341-8350 (2004).
46. Rivory, L.P., Slaviero, K.A. & Clarke, S.J. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br. J. Cancer 87, 277-280 (2002).
47. Shin, K.H., Choi, M.H., Lim, K.S., Yu, K.S., Jang, I.J. & Cho, J.Y. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profling and midazolam clearance. Clin. Pharmacol. Ther. 94, 601-609 (2013).
48. Luo, J., Solimini, N.L. & Elledge, S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837 (2009).
49. Gauttier, V., Judor, J.P., Le Guen, V., Cany, J., Ferry, N. & Conchon, S. Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer. Int. J. Cancer (2014); e-pub ahead of print 2 May 2014.
50. Gerner, M.Y., Heltemes-Harris, L.M., Fife, B.T. & Mescher, M.F. Cutting edge: IL-12 and type I IFN diferentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J. Immunol. 191, 1011-1015 (2013).
51. Hamzah, J., Nelson, D., Moldenhauer, G., Arnold, B., Hämmerling, G.J. & Ganss, R. Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J. Clin. Invest. 118, 1691-1699 (2008).
52. Jensen, S.M. et al. Signaling through OX40 enhances antitumor immunity. Semin. Oncol. 37, 524-532 (2010).
53. Sunman, J.A., Hawke, R.L., LeCluyse, E.L. & Kashuba, A.D. Kupfer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab. Dispos. 32, 359-363 (2004).
54. Elkahwaji, J. et al. Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem. Pharmacol. 57, 951-954 (1999).
55. Melero, I., Grimaldi, A.M., Perez-Gracia, J.L. & Ascierto, P.A. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin. Cancer Res. 19, 997-1008 (2013).
56. Hodi, F.S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
57. Prieto, P.A. et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin. Cancer Res. 18, 2039-2047 (2012).
58. O'Day, S.J. et al. Efcacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann. Oncol. 21, 1712-1717 (2010).
59. Wolchok, J.D. et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11, 155-164 (2010).
60. Ribas, A. et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31, 616-622 (2013).
61. Downey, S.G. et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 13, 6681-6688 (2007).
62. Harvey, R.D. Immunologic and clinical efects of targeting PD-1 in lung cancer. Clin. Pharmacol. Ther. 96, 214-223 (2014).
63. Topalian, S.L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
64. Yuan, J. et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specifc T cell responses in metastatic melanoma patients with clinical beneft. Proc. Natl. Acad. Sci. USA 105, 20410-20415 (2008).
65. Dulos, J. et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J. Immunother. 35, 169-178 (2012).
66. Hersh, E.M. et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest. New Drugs 29, 489-498 (2011).
67. Lynch, T.J. et al. Ipilimumab in combination with paclitaxel and carboplatin as frst-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 30, 2046-2054 (2012).
68. Reck, M. et al. Ipilimumab in combination with paclitaxel and carboplatin as frst-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann. Oncol. 24, 75-83 (2013).
69. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
70. Weber, J. et al. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two diferent chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun. 13, 7 (2013).
71. Di Giacomo, A.M. et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 13, 879-886 (2012).
72. Daponte, A. et al.; Southern Italy Cooperative Oncology Group (SICOG). Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma. J. Transl. Med. 11, 38 (2013).
73. Ribas, A., Hodi, F.S., Callahan, M., Konto, C. & Wolchok, J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365-1366 (2013).
74. Wolchok, J.D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
75. Lutz, U., Bittner, N., Ufer, M. & Lutz, W.K. Quantifcation of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS/MS, and gender-specifc evaluation of the metabolic ratio as biomarker of CYP3A activity. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 878, 97-101 (2010).